GlobalData on MSN8h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
News Medical on MSN3d
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetesTirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...
In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...
Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...
Medpage Today on MSN10d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback